Patent · US Active

Method for preparing immobilized arginine deiminase (ADI) and producing [14/15N]-L-citrulline

US12378563B2 · kind B2 · utility

0Cited by

0References

17Claims

0Family size

Assignee

SHANGHAI UNIVERSITY OF MEDICINE & HEALTH SCIENCES · CN

Inventors

Gang Huang · Nanhu, CN
Bin Li · Beijing, CN
Yue Li · Qingdao, CN

Key dates

Filing date	Oct 13, 2020
Grant date	Aug 5, 2025
Priority date	—
Expiry date	Oct 13, 2040

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Arginine deiminase (ADI)-containing genetically engineered Corynebacterium glutamicum (C. glutamicum), a fusion protein cipA-arc, use thereof, and a method for preparing [14/15N]-L-citrulline through enzymatic catalysis are provided. The ADI-containing genetically engineered Corynebacterium glutamicum (C. glutamicum) has a deposit number of CGMCC No. 19404, which expresses a fusion protein cipA-arc. Both the genetically engineered strain and the fusion protein cipA-arc can be used to convert [14/15N]-L-arginine into [14/15N]-L-citrulline.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.